Report: Sigma-Tau may sell a stake in company

Bloomberg cites sources close to Italy's Sigma-Tau who say that the company is considering selling a stake in the biotech following the death of its founder. Four Partners is advising the company, which is reportedly considering a deal that would value the company at $1.4 billion. Sigma-Tau has a pipeline of drugs in development for rare and neglected ailments. Story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.